It seems that CD73 might be a promising biomarker for the response to the anti‐PD‐1/PD‐L1 treatment in PC, and combination of CD73 blockade and anti‐PD‐ L1/PD‐1 mAb might be also a promising therapeutic strategy for PC. The gene discussed is NT5E; the disease is pachyonychia congenita.